Norris Medicines Ltd () News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 210607,
    "name": "Norris Medicines",
    "stock_name": "Norris Medicines",
    "full_name": "Norris Medicines Ltd",
    "name_url": "stocks-analysis/norris-medicines",
    "exchange": 0,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "15.00",
    "chg": 0.33,
    "chgp": "2.25%",
    "dir": 1,
    "prev_price": "14.67",
    "mcapval": "15.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 524414,
    "symbol": "",
    "ind_name": "Trading & Distributors",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE744C01029",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": "661 ",
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/norris-medicines-210607-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Norris Medicines Stock Falls to 52-Week Low of Rs.14 Amidst Prolonged Downtrend",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/norris-medicines-stock-hits-52-week-low-amidst-continued-downtrend-3746772",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NorrisMedicines_priceRelatedfactors_3746772.png",
        "date": "2025-12-04 12:42:02",
        "description": "Norris Medicines has reached a new 52-week low of Rs.14, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on the company’s financial and market position."
      },
      {
        "title": "Norris Medicines Stock Falls to 52-Week Low of Rs.14.02 Amidst Market Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/norris-medicines-stock-falls-to-52-week-low-of-rs1402-amidst-weak-fundamentals-3743429",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NorrisMedicines_priceRelatedfactors_3743429.png",
        "date": "2025-12-03 09:53:21",
        "description": "Norris Medicines has reached a new 52-week low of Rs.14.02, marking a significant decline in its stock price amid broader market fluctuations and sector underperformance. The stock's recent movement reflects ongoing challenges within the company’s financial metrics and market positioning."
      },
      {
        "title": "Norris Medicines Stock Hits 52-Week Low at Rs.14.02 Amid Market Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/norris-medicines-stock-hits-52-week-low-amidst-weak-financial-metrics-3743427",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NorrisMedicines_priceRelatedfactors_3743427.png",
        "date": "2025-12-03 09:53:09",
        "description": "Norris Medicines has reached a new 52-week low of Rs.14.02, marking a significant decline in its stock price amid broader market fluctuations and sector underperformance. The stock's current trading levels reflect ongoing pressures within the Trading & Distributors sector, contrasting with the broader market's relative strength."
      },
      {
        "title": "Norris Medicines Stock Falls to 52-Week Low of Rs.14.5 Amidst Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/norris-medicines-stock-falls-to-52-week-low-of-rs145-amidst-weak-financial-metrics-3738366",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NorrisMedicines_priceRelatedfactors_3738366.png",
        "date": "2025-12-01 11:12:06",
        "description": "Norris Medicines has reached a new 52-week low of Rs.14.5 today, marking a significant decline in its stock price amid continued underperformance relative to its sector and broader market indices."
      },
      {
        "title": "Norris Medicines Stock Falls to 52-Week Low of Rs.14.5 Amidst Market Underperformance",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/norris-medicines-stock-falls-to-52-week-low-of-rs145-amidst-weak-financial-metrics-3738361",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/NorrisMedicines_priceRelatedfactors_3738361.png",
        "date": "2025-12-01 11:11:57",
        "description": "Norris Medicines has reached a new 52-week low of Rs.14.5, marking a significant decline in its stock price as it continues to underperform relative to its sector and broader market indices. The stock's recent movement reflects ongoing challenges within the company’s financial metrics and market positioning."
      },
      {
        "title": "Norris Medicines Q2 FY26: Deepening Losses Despite Revenue Growth Signal Structural Distress",
        "link": "https://www.marketsmojo.com/news/result-analysis/norris-medicines-q2-fy26-deepening-losses-despite-revenue-growth-signal-structural-distress-3718705",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/NorrisMedicines_quaterlyResult_3718705.png",
        "date": "2025-11-18 15:49:54",
        "description": "Norris Medicines Limited, the Ankleshwar-based pharmaceutical manufacturer and distributor, reported a troubling second quarter for FY2026, with net losses widening to ₹0.72 crores despite a 57.48% year-on-year revenue increase. The micro-cap company, valued at just ₹15.00 crores, continues to struggle with operational inefficiencies and negative profitability metrics that have plagued its performance for multiple quarters. Trading at ₹15.93 on November 18, 2025, the stock reflects investor scepticism about the company's ability to achieve sustainable profitability."
      },
      {
        "title": "How has been the historical performance of Norris Medicines?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-norris-medicines-3704012",
        "imagepath": "",
        "date": "2025-11-15 00:22:00",
        "description": "Answer:\nThe historical performance of Norris Medicines shows a declining trend in net sales and profitability over the years, with significant losses reported in recent periods.\n\nBreakdown:\nNorris Medicines has experienced a downward trajectory in net sales, decreasing from 12.25 Cr in Mar'21 to 5.82 Cr in Mar'25. The total operating income followed a similar pattern, dropping from 16.27 Cr in Mar'19 to 5.82 Cr in Mar'25. The company's total expenditure, excluding depreciation, also decreased from 13.99 Cr in Mar'21 to 6.08 Cr in Mar'25, yet the operating profit (PBDIT) remained negative, with a loss of -0.20 Cr in Mar'25 compared to a profit of 0.93 Cr in Mar'23. Profit before tax has consistently been negative, culminating in a loss of -1.18 Cr in Mar'25. The profit after tax also reflected losses, amounting to -1.24 Cr in Mar'25, indicating persistent financial challenges. The company's total liabilities..."
      },
      {
        "title": "Are Norris Medicines latest results good or bad?",
        "link": "https://www.marketsmojo.com/news/result-analysis/are-norris-medicines-latest-results-good-or-bad-3702245",
        "imagepath": "",
        "date": "2025-11-14 19:32:13",
        "description": "Norris Medicines has released its financial results for the quarter ending June 2025, which indicate a notable shift in operational performance compared to the previous quarter. The company's net sales experienced a significant decline of 46.32% from the prior quarter, where it had reported a growth of 145.05%. This sharp decrease suggests challenges in sales generation during this period.\n\nAdditionally, the standalone net profit also reflected a decline of 34.78%, contrasting with a positive growth of 17.86% in the previous quarter. This indicates that the company faced difficulties in maintaining profitability.\n\nThe operating profit margin, excluding other income, saw a change to -9.42%, compared to -6.85% in the prior quarter, further highlighting the operational challenges faced by Norris Medicines.\n\nOverall, the results reveal a consistent performance in terms of evaluation, as the company saw an adjus..."
      },
      {
        "title": "When is the next results date for Norris Medicines?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-norris-medicines-3691230",
        "imagepath": "",
        "date": "2025-11-11 23:20:12",
        "description": "Norris Medicines will declare its results on 14 November 2025...."
      }
    ],
    "total": 244,
    "sid": "210607",
    "stock_news_url": "https://www.marketsmojo.com/news/norris-medicines-210607"
  },
  "announcements": [
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting Held Today I.E. Friday November 14 2025",
      "datetime": "14-Nov-2025",
      "details": "As per attachment.",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Intimation Under Regulation 29 Of SEBI Listing Obligation And Disclosure Requirements 2015 For Holding Board Meeting For Approval Of Un-Audited Financial Results For The Quarter Ended September 30Th 2025 And Other Matters.",
      "datetime": "08-Nov-2025",
      "details": "Norris Medicines Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/11/2025 inter alia to consider and approve As per attachment",
      "source": "BSE"
    },
    {
      "caption": "Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018",
      "datetime": "14-Oct-2025",
      "details": "As per attachments.",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Norris Medicines Stock Falls to 52-Week Low of Rs.14 Amidst Prolonged Downtrend

2025-12-04 12:42:02

Norris Medicines has reached a new 52-week low of Rs.14, marking a significant decline amid a sustained downward trend. The stock has underperformed its sector and broader market indices, reflecting ongoing pressures on the company’s financial and market position.

Norris Medicines Stock Falls to 52-Week Low of Rs.14.02 Amidst Market Pressure

2025-12-03 09:53:21

Norris Medicines has reached a new 52-week low of Rs.14.02, marking a significant decline in its stock price amid broader market fluctuations and sector underperformance. The stock's recent movement reflects ongoing challenges within the company’s financial metrics and market positioning.

Norris Medicines Stock Hits 52-Week Low at Rs.14.02 Amid Market Pressure

2025-12-03 09:53:09

Norris Medicines has reached a new 52-week low of Rs.14.02, marking a significant decline in its stock price amid broader market fluctuations and sector underperformance. The stock's current trading levels reflect ongoing pressures within the Trading & Distributors sector, contrasting with the broader market's relative strength.

Norris Medicines Stock Falls to 52-Week Low of Rs.14.5 Amidst Underperformance

2025-12-01 11:12:06

Norris Medicines has reached a new 52-week low of Rs.14.5 today, marking a significant decline in its stock price amid continued underperformance relative to its sector and broader market indices.

Norris Medicines Stock Falls to 52-Week Low of Rs.14.5 Amidst Market Underperformance

2025-12-01 11:11:57

Norris Medicines has reached a new 52-week low of Rs.14.5, marking a significant decline in its stock price as it continues to underperform relative to its sector and broader market indices. The stock's recent movement reflects ongoing challenges within the company’s financial metrics and market positioning.

Norris Medicines Q2 FY26: Deepening Losses Despite Revenue Growth Signal Structural Distress

2025-11-18 15:49:54

Norris Medicines Limited, the Ankleshwar-based pharmaceutical manufacturer and distributor, reported a troubling second quarter for FY2026, with net losses widening to ₹0.72 crores despite a 57.48% year-on-year revenue increase. The micro-cap company, valued at just ₹15.00 crores, continues to struggle with operational inefficiencies and negative profitability metrics that have plagued its performance for multiple quarters. Trading at ₹15.93 on November 18, 2025, the stock reflects investor scepticism about the company's ability to achieve sustainable profitability.

How has been the historical performance of Norris Medicines?

2025-11-15 00:22:00

Answer: The historical performance of Norris Medicines shows a declining trend in net sales and profitability over the years, with significant losses reported in recent periods. Breakdown: Norris Medicines has experienced a downward trajectory in net sales, decreasing from 12.25 Cr in Mar'21 to 5.82 Cr in Mar'25. The total operating income followed a similar pattern, dropping from 16.27 Cr in Mar'19 to 5.82 Cr in Mar'25. The company's total expenditure, excluding depreciation, also decreased from 13.99 Cr in Mar'21 to 6.08 Cr in Mar'25, yet the operating profit (PBDIT) remained negative, with a loss of -0.20 Cr in Mar'25 compared to a profit of 0.93 Cr in Mar'23. Profit before tax has consistently been negative, culminating in a loss of -1.18 Cr in Mar'25. The profit after tax also reflected losses, amounting to -1.24 Cr in Mar'25, indicating persistent financial challenges. The company's total liabilities...

Are Norris Medicines latest results good or bad?

2025-11-14 19:32:13

Norris Medicines has released its financial results for the quarter ending June 2025, which indicate a notable shift in operational performance compared to the previous quarter. The company's net sales experienced a significant decline of 46.32% from the prior quarter, where it had reported a growth of 145.05%. This sharp decrease suggests challenges in sales generation during this period. Additionally, the standalone net profit also reflected a decline of 34.78%, contrasting with a positive growth of 17.86% in the previous quarter. This indicates that the company faced difficulties in maintaining profitability. The operating profit margin, excluding other income, saw a change to -9.42%, compared to -6.85% in the prior quarter, further highlighting the operational challenges faced by Norris Medicines. Overall, the results reveal a consistent performance in terms of evaluation, as the company saw an adjus...

When is the next results date for Norris Medicines?

2025-11-11 23:20:12

Norris Medicines will declare its results on 14 November 2025....

View All News